<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1020-3397</journal-id>
<journal-title><![CDATA[Eastern Mediterranean Health Journal]]></journal-title>
<abbrev-journal-title><![CDATA[East. Mediterr. health j.]]></abbrev-journal-title>
<issn>1020-3397</issn>
<publisher>
<publisher-name><![CDATA[Alexandria: WHO, Regional Office for the Eastern Mediterranean]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1020-33972007000400015</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Intravaginal prostaglandin-E2 for cervical priming and induction of labour]]></article-title>
<article-title xml:lang="fr"><![CDATA[Administration intravaginale de prostaglandine E2 pour la maturation du col utérin et le déclenchement du travail]]></article-title>
<article-title xml:lang="ar"><![CDATA[&#1575;&#1604;&#1576;&#1585;&#1608;&#1587;&#1578;&#1575;&#1594;&#1604;&#1575;&#1606;&#1583;&#1610;&#1606; E2 &#1583;&#1575;&#1582;&#1604; &#1575;&#1604;&#1605;&#1607;&#1576;&#1604; &#1604;&#1578;&#1581;&#1585;&#1610;&#1590; &#1575;&#1604;&#1605;&#1582;&#1575;&#1590; &#1608;&#1578;&#1607;&#1610;&#1574;&#1577; &#1593;&#1606;&#1602; &#1575;&#1604;&#1585;&#1581;&#1605;]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Al-Taani]]></surname>
<given-names><![CDATA[M.I.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Royal Medical Services Prince Rashed Ben Al-Hassan Hospital Department of Obstetrics and Gynecology]]></institution>
<addr-line><![CDATA[Irbid ]]></addr-line>
<country>Jordan</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2007</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2007</year>
</pub-date>
<volume>13</volume>
<numero>4</numero>
<fpage>855</fpage>
<lpage>861</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://eastern.mediterranean.scielo.org/scielo.php?script=sci_arttext&amp;pid=S1020-33972007000400015&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><self-uri xlink:href="http://eastern.mediterranean.scielo.org/scielo.php?script=sci_abstract&amp;pid=S1020-33972007000400015&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><self-uri xlink:href="http://eastern.mediterranean.scielo.org/scielo.php?script=sci_pdf&amp;pid=S1020-33972007000400015&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[A prospective study examined the safety, efficacy and labour outcome in 436 women undergoing labour induction using intravaginal prostaglandin E2. Women with singleton pregnancies (235 nulliparas and 201 multiparas) were recruited if they had a clinically unfavourable cervix, and indications for induction. The mean (standard deviation) interval from initiation to delivery was statistically significantly shorter in multiparas than nulliparas: 13.5 hours (SD 1.8) versus 15.5 hours (SD 2.4). No more than 2 × 3 mg tablets were needed to achieve a clinically feasible cervix for amniotomy. The overall need for oxytocin augmentation of labour was 42%, significantly higher in nulliparas (47%) than multiparas (35%). Intrapartum complications, caesarean section and perinatal deaths showed no statistically significant differences between the groups.]]></p></abstract>
<abstract abstract-type="short" xml:lang="fr"><p><![CDATA[Une étude prospective a évalué la tolérance, l’efficacité et l’issue du travail chez 436 femmes (235 nullipares et 201 multipares) après déclenchement du travail par administration intravaginale de prostaglandine E2. Les critères de recrutement étaient les suivants : grossesse simple, risque avéré d’inertie du col utérin et indications pour un déclenchement du travail. L’intervalle de temps moyen (E.T. : écart type) entre l’instauration de la méthode et l’accouchement s’est révélé plus bref chez les multipares que chez les nullipares : 13,5 heures (E.T. : 1,8) versus 15,5 heures (E.T. : 2,4). Pas plus de 2 comprimés dosés à 3 mg n’ont été nécessaires pour obtenir un col cliniquement accessible à l’amniotomie. La fréquence globale du recours à la stimulation du travail par administration d’ocytocine a été de 42 %, s’avérant significativement plus élevée chez les nullipares (47 %) que chez les multipares (35 %). Les complications intrapartum, les césariennes et les morts périnatales n’ont laissé apparaître aucune différence statistiquement significative entre les groupes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="ar"><p><![CDATA[&#1571;&#1615;&#1580;&#1585;&#1610;&#1578; &#1583;&#1585;&#1575;&#1587;&#1577; &#1575;&#1587;&#1578;&#1576;&#1575;&#1602;&#1610;&#1577; &#1578;&#1600;&#1578;&#1606;&#1575;&#1608;&#1604; &#1587;&#1604;&#1575;&#1605;&#1577; &#1608;&#1606;&#1580;&#1575;&#1593;&#1577; &#1608;&#1581;&#1589;&#1610;&#1604;&#1577; &#1575;&#1604;&#1605;&#1582;&#1575;&#1590; &#1601;&#1610; 436 &#1575;&#1605;&#1585;&#1571;&#1577; &#1571;&#1615;&#1580;&#1585;&#1610; &#1604;&#1607;&#1606; &#1578;&#1581;&#1585;&#1610;&#1590; &#1604;&#1604;&#1605;&#1582;&#1575;&#1590; &#1576;&#1575;&#1604;&#1576;&#1585;&#1608;&#1587;&#1578;&#1575;&#1594;&#1604;&#1575;&#1606;&#1583;&#1610;&#1606; E2&#1583;&#1575;&#1582;&#1604; &#1575;&#1604;&#1605;&#1607;&#1576;&#1604;. &#1608;&#1602;&#1583; &#1575;&#1582;&#1578;&#1610;&#1585;&#1578; &#1575;&#1604;&#1606;&#1587;&#1608;&#1577; &#1584;&#1608;&#1575;&#1578; &#1575;&#1604;&#1571;&#1581;&#1605;&#1575;&#1604; &#1575;&#1604;&#1605;&#1601;&#1585;&#1583;&#1577; &#1575;&#1604;&#1571;&#1580;&#1606;&#1617;&#1614;&#1577;&#1548; (&#1607;&#1606;&#1617; 235 &#1582;&#1614;&#1585;&#1615;&#1608;&#1587;&#1575;&#1611; (&#1576;&#1603;&#1585;&#1610;&#1577;) &#1608;20 &#1608;&#1614;&#1604;&#1615;&#1608;&#1583;&#1575;&#1611; (&#1605;&#1578;&#1593;&#1583;&#1617;&#1616;&#1583;&#1577; &#1575;&#1604;&#1608;&#1604;&#1575;&#1583;&#1577;) &#1605;&#1600;&#1605;&#1617;&#1614;&#1606; &#1571;&#1593;&#1606;&#1575;&#1602;&#1615; &#1571;&#1585;&#1581;&#1575;&#1605;&#1607;&#1606; &#1594;&#1610;&#1585; &#1605;&#1604;&#1575;&#1574;&#1605;&#1577; &#1587;&#1585;&#1610;&#1585;&#1610;&#1575;&#1611;&#1548; &#1605;&#1593; &#1608;&#1580;&#1608;&#1583; &#1575;&#1587;&#1578;&#1591;&#1576;&#1575;&#1576; &#1604;&#1578;&#1581;&#1585;&#1610;&#1590; &#1575;&#1604;&#1605;&#1582;&#1575;&#1590;. &#1608;&#1602;&#1583; &#1603;&#1575;&#1606;&#1578; &#1575;&#1604;&#1601;&#1578;&#1600;&#1585;&#1577; &#1575;&#1604;&#1608;&#1587;&#1591;&#1610;&#1577; &#1605;&#1606; &#1576;&#1583;&#1569; &#1575;&#1604;&#1593;&#1605;&#1604; &#1576;&#1607;&#1584;&#1607; &#1575;&#1604;&#1583;&#1585;&#1575;&#1587;&#1577; &#1608;&#1581;&#1578;&#1609; &#1575;&#1604;&#1608;&#1604;&#1575;&#1583;&#1577; &#1571;&#1602;&#1589;&#1585; &#1576;&#1583;&#1585;&#1580;&#1577; &#1610;&#1615;&#1593;&#1618;&#1578;&#1614;&#1583;&#1617;&#1615; &#1576;&#1607;&#1575; &#1573;&#1581;&#1589;&#1575;&#1574;&#1610;&#1575;&#1611; &#1604;&#1583;&#1609; &#1575;&#1604;&#1608;&#1614;&#1604;&#1608;&#1615;&#1583;&#1575;&#1578; &#1605;&#1606;&#1607;&#1575; &#1604;&#1583;&#1609; &#1575;&#1604;&#1582;&#1614;&#1585;&#1615;&#1608;&#1587;&#1575;&#1578; (&#1575;&#1604;&#1576;&#1603;&#1585;&#1610;&#1575;&#1578;)&#1548; &#1573;&#1584;&#1618; &#1576;&#1604;&#1594;&#1578; &#1604;&#1583;&#1609; &#1575;&#1604;&#1608;&#1614;&#1604;&#1615;&#1608;&#1583;&#1575;&#1578; 13.5 &#1587;&#1575;&#1593;&#1577; (± 1.8) &#1605;&#1602;&#1575;&#1576;&#1604; 15.5 &#1587;&#1575;&#1593;&#1577; (±2.4) &#1604;&#1583;&#1609; &#1575;&#1604;&#1582;&#1614;&#1585;&#1615;&#1608;&#1587;&#1575;&#1578;. &#1608;&#1604;&#1605; &#1578;&#1600;&#1578;&#1580;&#1575;&#1608;&#1586; &#1575;&#1604;&#1581;&#1575;&#1580;&#1577; &#1604;&#1604;&#1608;&#1589;&#1608;&#1604; &#1573;&#1604;&#1609; &#1593;&#1606;&#1602; &#1585;&#1581;&#1605; &#1610;&#1605;&#1603;&#1606; &#1587;&#1585;&#1610;&#1585;&#1610;&#1575;&#1611; &#1573;&#1580;&#1585;&#1575;&#1569; &#1576;&#1614;&#1590;&#1618;&#1593; &#1575;&#1604;&#1587;&#1617;&#1614;&#1604;&#1614;&#1609; &#1605;&#1606; &#1582;&#1604;&#1575;&#1604;&#1607;&#1548; &#1602;&#1585;&#1589;&#1614;&#1610;&#1618;&#1606; &#1605;&#1606; &#1575;&#1604;&#1576;&#1585;&#1608;&#1587;&#1578;&#1575;&#1594;&#1604;&#1575;&#1606;&#1583;&#1610;&#1606; E2 &#1605;&#1606; &#1593;&#1610;&#1600;&#1575;&#1585; 3 &#1605;&#1594;. &#1608;&#1602;&#1583; &#1576;&#1604;&#1594;&#1578; &#1575;&#1604;&#1581;&#1575;&#1580;&#1577; &#1575;&#1604;&#1573;&#1580;&#1605;&#1575;&#1604;&#1610;&#1577; &#1604;&#1604;&#1571;&#1608;&#1603;&#1587;&#1610; &#1578;&#1608;&#1587;&#1610;&#1606; &#1604;&#1586;&#1610;&#1575;&#1583;&#1577; &#1575;&#1604;&#1605;&#1582;&#1575;&#1590; 42%&#1548; &#1608;&#1607;&#1608; &#1571;&#1603;&#1579;&#1585; &#1576;&#1605;&#1602;&#1583;&#1575;&#1585; &#1610;&#1615;&#1593;&#1578;&#1583;&#1617;&#1615; &#1576;&#1607; &#1573;&#1581;&#1589;&#1575;&#1574;&#1610;&#1575;&#1611; &#1604;&#1583;&#1609; &#1575;&#1604;&#1576;&#1603;&#1585;&#1610;&#1575;&#1578; (47%) &#1605;&#1600;&#1605;&#1617;&#1614;&#1575; &#1604;&#1600;&#1583;&#1609; &#1575;&#1604;&#1608;&#1614;&#1604;&#1608;&#1615;&#1583;&#1575;&#1578; (35%)&#1548; &#1601;&#1610; &#1581;&#1610;&#1606; &#1604;&#1605; &#1610;&#1588;&#1575;&#1607;&#1583; &#1571;&#1610;&#1617;&#1615; &#1575;&#1582;&#1578;&#1604;&#1575;&#1601; &#1610;&#1615;&#1593;&#1618;&#1578;&#1614;&#1583;&#1617;&#1615; &#1576;&#1607; &#1573;&#1581;&#1589;&#1575;&#1574;&#1610;&#1575;&#1611; &#1576;&#1610;&#1606; &#1575;&#1604;&#1605;&#1580;&#1605;&#1608;&#1593;&#1578;&#1614;&#1610;&#1618;&#1606;&#1548; &#1576;&#1575;&#1604;&#1606;&#1587;&#1576;&#1577; &#1604;&#1604;&#1605;&#1590;&#1575;&#1593;&#1601;&#1575;&#1578; &#1571;&#1579;&#1606;&#1575;&#1569; &#1575;&#1604;&#1605;&#1582;&#1575;&#1590; &#1571;&#1608; &#1590;&#1585;&#1608;&#1585;&#1577; &#1573;&#1580;&#1585;&#1575;&#1569; &#1575;&#1604;&#1593;&#1605;&#1604;&#1610;&#1577; &#1575;&#1604;&#1602;&#1610;&#1589;&#1585;&#1610;&#1577; &#1571;&#1608; &#1575;&#1604;&#1608;&#1601;&#1610;&#1575;&#1578; &#1581;&#1608;&#1575;&#1604;&#1610; &#1575;&#1604;&#1608;&#1604;&#1575;&#1583;&#1577;.]]></p></abstract>
</article-meta>
</front><body><![CDATA[ <p align="right"><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESEARCH      ARTICLE</b></font></p>       <p>&nbsp;</p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Intravaginal      prostaglandin-E2 for cervical priming and induction of labour </b></font></p>       <p>&nbsp;</p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Administration      intravaginale de prostaglandine E2 pour la maturation du col utérin et le      déclenchement du travail </b></font></p>       <p>&nbsp;</p>        <p  align="right"><b><font face="Verdana, Arial, Helvetica, sans-serif" size="2">&#1575;&#1604;&#1576;&#1585;&#1608;&#1587;&#1578;&#1575;&#1594;&#1604;&#1575;&#1606;&#1583;&#1610;&#1606;    E2 &#1583;&#1575;&#1582;&#1604; &#1575;&#1604;&#1605;&#1607;&#1576;&#1604; &#1604;&#1578;&#1581;&#1585;&#1610;&#1590;    &#1575;&#1604;&#1605;&#1582;&#1575;&#1590; &#1608;&#1578;&#1607;&#1610;&#1574;&#1577;    &#1593;&#1606;&#1602; &#1575;&#1604;&#1585;&#1581;&#1605;</font></b></p>       <p>&nbsp;</p>       <p>&nbsp;</p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> <b>M.I. Al-Taani</b></font></p>     ]]></body>
<body><![CDATA[<p  align="right"><font face="Verdana, Arial, Helvetica, sans-serif" size="2">&#1605;&#1581;&#1605;&#1583;    &#1573;&#1576;&#1585;&#1575;&#1607;&#1610;&#1605; &#1575;&#1604;&#1591;&#1593;&#1575;&#1606;&#1610;</font></p>       <p  ><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Department      of Obstetrics and Gynecology, Prince Rashed Ben Al-Hassan Hospital, Royal      Medical Services, Irbid, Jordan (Correspondence to M.I. Al-Taani: <a href="mailto:maltaani@yahoo.com">maltaani@yahoo.com</a>)</font></p>       <p  align="right">&nbsp;</p>       <p  align="right">&nbsp;</p> <hr size="1" noshade>        <p><b><font face="Verdana, Arial, Helvetica, sans-serif" size="2">ABSTRACT</font></b></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> A prospective      study examined the safety, efficacy and labour outcome in 436 women undergoing      labour induction using intravaginal prostaglandin E2. Women with singleton      pregnancies (235 nulliparas and 201 multiparas) were recruited if they had      a clinically unfavourable cervix, and indications for induction. The mean      (standard deviation) interval from initiation to delivery was statistically      significantly shorter in multiparas than nulliparas: 13.5 hours (SD 1.8) versus      15.5 hours (SD 2.4). No more than 2 × 3 mg tablets were needed to achieve      a clinically feasible cervix for amniotomy. The overall need for oxytocin      augmentation of labour was 42%, significantly higher in nulliparas (47%) than      multiparas (35%). Intrapartum complications, caesarean section and perinatal      deaths showed no statistically significant differences between the groups.      </font></p>   <hr size="1" noshade>      <p> <font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>R&Eacute;SUM&Eacute;</b></font>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> Une étude prospective      a évalué la tolérance, l’efficacité et l’issue du travail chez 436 femmes      (235 nullipares et 201 multipares) après déclenchement du travail par administration      intravaginale de prostaglandine E2. Les critères de recrutement étaient les      suivants : grossesse simple, risque avéré d’inertie du col utérin et indications      pour un déclenchement du travail. L’intervalle de temps moyen (E.T. : écart      type) entre l’instauration de la méthode et l’accouchement s’est révélé plus      bref chez les multipares que chez les nullipares : 13,5 heures (E.T. : 1,8)      versus 15,5 heures (E.T. : 2,4). Pas plus de 2 comprimés dosés à 3 mg n’ont      été nécessaires pour obtenir un col cliniquement accessible à l’amniotomie.      La fréquence globale du recours à la stimulation du travail par administration      d’ocytocine a été de 42 %, s’avérant significativement plus élevée chez les      nullipares (47 %) que chez les multipares (35 %). Les complications intrapartum,      les césariennes et les morts périnatales n’ont laissé apparaître aucune différence      statistiquement significative entre les groupes.</font></p>   <hr size="1" noshade>        <p  align="right"><b><font face="Verdana, Arial, Helvetica, sans-serif" size="2">&#1575;&#1604;&#1582;&#1604;&#1575;&#1589;&#1600;&#1577;</font></b></p>     <p  align="right"><font face="Verdana, Arial, Helvetica, sans-serif" size="2">&#1571;&#1615;&#1580;&#1585;&#1610;&#1578;    &#1583;&#1585;&#1575;&#1587;&#1577; &#1575;&#1587;&#1578;&#1576;&#1575;&#1602;&#1610;&#1577;    &#1578;&#1600;&#1578;&#1606;&#1575;&#1608;&#1604; &#1587;&#1604;&#1575;&#1605;&#1577;    &#1608;&#1606;&#1580;&#1575;&#1593;&#1577; &#1608;&#1581;&#1589;&#1610;&#1604;&#1577;    &#1575;&#1604;&#1605;&#1582;&#1575;&#1590; &#1601;&#1610; 436 &#1575;&#1605;&#1585;&#1571;&#1577;    &#1571;&#1615;&#1580;&#1585;&#1610; &#1604;&#1607;&#1606; &#1578;&#1581;&#1585;&#1610;&#1590;    &#1604;&#1604;&#1605;&#1582;&#1575;&#1590; &#1576;&#1575;&#1604;&#1576;&#1585;&#1608;&#1587;&#1578;&#1575;&#1594;&#1604;&#1575;&#1606;&#1583;&#1610;&#1606;    E2&#1583;&#1575;&#1582;&#1604; &#1575;&#1604;&#1605;&#1607;&#1576;&#1604;. &#1608;&#1602;&#1583;    &#1575;&#1582;&#1578;&#1610;&#1585;&#1578; &#1575;&#1604;&#1606;&#1587;&#1608;&#1577;    &#1584;&#1608;&#1575;&#1578; &#1575;&#1604;&#1571;&#1581;&#1605;&#1575;&#1604;    &#1575;&#1604;&#1605;&#1601;&#1585;&#1583;&#1577; &#1575;&#1604;&#1571;&#1580;&#1606;&#1617;&#1614;&#1577;&#1548;    (&#1607;&#1606;&#1617; 235 &#1582;&#1614;&#1585;&#1615;&#1608;&#1587;&#1575;&#1611;    (&#1576;&#1603;&#1585;&#1610;&#1577;) &#1608;20 &#1608;&#1614;&#1604;&#1615;&#1608;&#1583;&#1575;&#1611;    (&#1605;&#1578;&#1593;&#1583;&#1617;&#1616;&#1583;&#1577; &#1575;&#1604;&#1608;&#1604;&#1575;&#1583;&#1577;)    &#1605;&#1600;&#1605;&#1617;&#1614;&#1606; &#1571;&#1593;&#1606;&#1575;&#1602;&#1615;    &#1571;&#1585;&#1581;&#1575;&#1605;&#1607;&#1606; &#1594;&#1610;&#1585; &#1605;&#1604;&#1575;&#1574;&#1605;&#1577;    &#1587;&#1585;&#1610;&#1585;&#1610;&#1575;&#1611;&#1548; &#1605;&#1593; &#1608;&#1580;&#1608;&#1583;    &#1575;&#1587;&#1578;&#1591;&#1576;&#1575;&#1576; &#1604;&#1578;&#1581;&#1585;&#1610;&#1590;    &#1575;&#1604;&#1605;&#1582;&#1575;&#1590;. &#1608;&#1602;&#1583; &#1603;&#1575;&#1606;&#1578;    &#1575;&#1604;&#1601;&#1578;&#1600;&#1585;&#1577; &#1575;&#1604;&#1608;&#1587;&#1591;&#1610;&#1577;    &#1605;&#1606; &#1576;&#1583;&#1569; &#1575;&#1604;&#1593;&#1605;&#1604; &#1576;&#1607;&#1584;&#1607;    &#1575;&#1604;&#1583;&#1585;&#1575;&#1587;&#1577; &#1608;&#1581;&#1578;&#1609;    &#1575;&#1604;&#1608;&#1604;&#1575;&#1583;&#1577; &#1571;&#1602;&#1589;&#1585;    &#1576;&#1583;&#1585;&#1580;&#1577; &#1610;&#1615;&#1593;&#1618;&#1578;&#1614;&#1583;&#1617;&#1615;    &#1576;&#1607;&#1575; &#1573;&#1581;&#1589;&#1575;&#1574;&#1610;&#1575;&#1611;    &#1604;&#1583;&#1609; &#1575;&#1604;&#1608;&#1614;&#1604;&#1608;&#1615;&#1583;&#1575;&#1578;    &#1605;&#1606;&#1607;&#1575; &#1604;&#1583;&#1609; &#1575;&#1604;&#1582;&#1614;&#1585;&#1615;&#1608;&#1587;&#1575;&#1578;    (&#1575;&#1604;&#1576;&#1603;&#1585;&#1610;&#1575;&#1578;)&#1548; &#1573;&#1584;&#1618;    &#1576;&#1604;&#1594;&#1578; &#1604;&#1583;&#1609; &#1575;&#1604;&#1608;&#1614;&#1604;&#1615;&#1608;&#1583;&#1575;&#1578;    13.5 &#1587;&#1575;&#1593;&#1577; (± 1.8) &#1605;&#1602;&#1575;&#1576;&#1604;    15.5 &#1587;&#1575;&#1593;&#1577; (±2.4) &#1604;&#1583;&#1609; &#1575;&#1604;&#1582;&#1614;&#1585;&#1615;&#1608;&#1587;&#1575;&#1578;.    &#1608;&#1604;&#1605; &#1578;&#1600;&#1578;&#1580;&#1575;&#1608;&#1586; &#1575;&#1604;&#1581;&#1575;&#1580;&#1577;    &#1604;&#1604;&#1608;&#1589;&#1608;&#1604; &#1573;&#1604;&#1609; &#1593;&#1606;&#1602;    &#1585;&#1581;&#1605; &#1610;&#1605;&#1603;&#1606; &#1587;&#1585;&#1610;&#1585;&#1610;&#1575;&#1611;    &#1573;&#1580;&#1585;&#1575;&#1569; &#1576;&#1614;&#1590;&#1618;&#1593; &#1575;&#1604;&#1587;&#1617;&#1614;&#1604;&#1614;&#1609;    &#1605;&#1606; &#1582;&#1604;&#1575;&#1604;&#1607;&#1548; &#1602;&#1585;&#1589;&#1614;&#1610;&#1618;&#1606;    &#1605;&#1606; &#1575;&#1604;&#1576;&#1585;&#1608;&#1587;&#1578;&#1575;&#1594;&#1604;&#1575;&#1606;&#1583;&#1610;&#1606;    E2 &#1605;&#1606; &#1593;&#1610;&#1600;&#1575;&#1585; 3 &#1605;&#1594;. &#1608;&#1602;&#1583;    &#1576;&#1604;&#1594;&#1578; &#1575;&#1604;&#1581;&#1575;&#1580;&#1577; &#1575;&#1604;&#1573;&#1580;&#1605;&#1575;&#1604;&#1610;&#1577;    &#1604;&#1604;&#1571;&#1608;&#1603;&#1587;&#1610; &#1578;&#1608;&#1587;&#1610;&#1606;    &#1604;&#1586;&#1610;&#1575;&#1583;&#1577; &#1575;&#1604;&#1605;&#1582;&#1575;&#1590;    42%&#1548; &#1608;&#1607;&#1608; &#1571;&#1603;&#1579;&#1585; &#1576;&#1605;&#1602;&#1583;&#1575;&#1585;    &#1610;&#1615;&#1593;&#1578;&#1583;&#1617;&#1615; &#1576;&#1607; &#1573;&#1581;&#1589;&#1575;&#1574;&#1610;&#1575;&#1611;    &#1604;&#1583;&#1609; &#1575;&#1604;&#1576;&#1603;&#1585;&#1610;&#1575;&#1578;    (47%) &#1605;&#1600;&#1605;&#1617;&#1614;&#1575; &#1604;&#1600;&#1583;&#1609;    &#1575;&#1604;&#1608;&#1614;&#1604;&#1608;&#1615;&#1583;&#1575;&#1578; (35%)&#1548;    &#1601;&#1610; &#1581;&#1610;&#1606; &#1604;&#1605; &#1610;&#1588;&#1575;&#1607;&#1583;    &#1571;&#1610;&#1617;&#1615; &#1575;&#1582;&#1578;&#1604;&#1575;&#1601; &#1610;&#1615;&#1593;&#1618;&#1578;&#1614;&#1583;&#1617;&#1615;    &#1576;&#1607; &#1573;&#1581;&#1589;&#1575;&#1574;&#1610;&#1575;&#1611; &#1576;&#1610;&#1606;    &#1575;&#1604;&#1605;&#1580;&#1605;&#1608;&#1593;&#1578;&#1614;&#1610;&#1618;&#1606;&#1548;    &#1576;&#1575;&#1604;&#1606;&#1587;&#1576;&#1577; &#1604;&#1604;&#1605;&#1590;&#1575;&#1593;&#1601;&#1575;&#1578;    &#1571;&#1579;&#1606;&#1575;&#1569; &#1575;&#1604;&#1605;&#1582;&#1575;&#1590;    &#1571;&#1608; &#1590;&#1585;&#1608;&#1585;&#1577; &#1573;&#1580;&#1585;&#1575;&#1569;    &#1575;&#1604;&#1593;&#1605;&#1604;&#1610;&#1577; &#1575;&#1604;&#1602;&#1610;&#1589;&#1585;&#1610;&#1577;    &#1571;&#1608; &#1575;&#1604;&#1608;&#1601;&#1610;&#1575;&#1578; &#1581;&#1608;&#1575;&#1604;&#1610;    &#1575;&#1604;&#1608;&#1604;&#1575;&#1583;&#1577;.</font></p>   <hr size="1" noshade>       ]]></body>
<body><![CDATA[<p>&nbsp;</p>       <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Labour induction      has become commonplace in modern obstetrics and is indicated in medical, obstetric      and fetal conditions in which prolongation of pregnancy would jeopardize maternal      and fetal well-being and in which there are no contraindications to the use      of labour induction methods. The process of cervical ripening is believed      to be controlled by certain hormones, in particular prostaglandin E2 (PGE2),      that play a role in triggering uterine contractile activity &#91;<i>1</i>&#93;. The      use of prostaglandins for cervical ripening and induction of labour administered      by any route has been reported to improve the rate of vaginal delivery, and      decrease the rate of caesarean section and instrument deliveries &#91;<i>2,3</i>&#93;.      </font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Because pregnancies      indicated for induction are at higher risk of perinatal morbidity and mortality,      this creates a stressful environment for women and physicians alike. A pregnancy      requiring induction of labour is a decision dilemma between facing the problems      of an unfavourable cervix at induction and those of increased perinatal complications      if it is decided to let the pregnancy continue. PGE2 has been shown to be      safe and efficacious in promoting pre-induction cervical ripening and in initiating      labour &#91;<i>4,5</i>&#93;.</font></p>        <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Induction of labour    is a common procedure in our unit. The total number of deliveries conducted    in our hospital during the study period (12 months) was 5069. The caesarean    section rate was 16.4%, while the rate of assisted vaginal deliveries was 1.9%.    The total number of inductions of labour was 1059 (20.9%) and 436 were induced    using vaginal PGE2. This study assessed the efficacy, safety and outcome of    vaginal PGE2 pessary for the ripening of the cervix and induction of labour    in this group of women, comparing multiparas and nulliparas.</font></p>     <p>&nbsp;</p>        <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Methods</b></font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">This prospective      study took place between September 2003 and August 2004 at Prince Rashed Ben      Al-Hassan Military Hospital, Irbid, Jordan. A total of 436 pregnant women      were recruited for the study who had a clinically unfavourable cervix and      indications for labour induction. Patients were considered eligible if they      had a singleton pregnancy, vertex presentation, intact membranes, and Bishop      score &#8804; 5. Women with ruptured membranes, contraindications for vaginal      birth, previous caesarean section and unexplained antepartum haemorrhage were      excluded.</font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Upon admission      for induction, the estimated date of confinement was reviewed based on reliable      menstrual history obtained at early antenatal booking when early gestation      was calculated from the last menstrual period. This was confirmed by sonograms      from the 1st and 2nd trimester, before 20 weeks gestational age. Full physical      and pelvic examination was performed for all the women together with a nonstress      test and sonogram (to evaluate amniotic fluid). Intravenous access was obtained      and baseline laboratory tests were done. A dinoprostone 3-mg vaginal pessary      was inserted in the posterior vaginal fornix. This was repeated after 6 hours      if the signs of labour were not detected.</font></p>       ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Amniotomy was      performed within 1-2 hours of the diagnosis of labour (or as soon as clinically      feasible), unless membranes spontaneously ruptured. Labour progress was monitored      by pelvic examination every 2 hours. Labour abnormalities were defined by      Friedman’s criteria &#91;<i>6</i>&#93;. In this case, oxytocin augmentation was started      (with Syntocinon) and administered in the manner outlined by Seitchik and      Castillo &#91;<i>7</i>&#93;. This was stopped in cases of uterine hyperstimulation      or changes suggestive of fetal hypoxia. Continuous fetal heart rate monitoring      during labour was performed in each parturient. Fetal distress was defined      as the occurrence of fetal heart rate abnormalities that require the attending      physician to complete the delivery either by assisted vaginal or abdominal      delivery. The presence of meconium was noted either at the time of amniotomy      or subsequently during labour. Every infant was given immediate suctioning      of the oropharynx at the time of delivery. </font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Statistical      analysis</b></font></p>        <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Student <i>t</i>-test    was used for continuous data, while for categorical data, the Fisher exact test    or chi-squared test was used where appropriate. Significance was considered    as <i>P</i> &lt; 0.05.</font></p>     <p>&nbsp;</p>        <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Of the 436 women      induced with PGE2, 235 were nulliparas and 201 multiparas. Maternal age ranged      between 17 and 36 years for nulliparas and 23 and 45 years for multiparas.      Gestational age ranged between 29 and 42 weeks for nullipara and 30 and 42      weeks for multiparas.</font></p>        <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#tab01">Table    1</a> presents the indications for induction. Postdates, pre-eclampsia, diabetes    and presumed macrosomia were the most frequent indications in both groups. These    were significantly higher (<i>P</i> = 0.001), whereas suspected intrauterine    growth restriction, oligohydramnios and non-reassuring cardiotocography were    not significant. </font></p>     <p><a name="tab01"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/emhj/v13n4/a14tab01.gif"></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#tab02">Table    2</a> shows the outcomes of labour and delivery. Overall 42% of the women needed    oxytocin for augmentation of labour. The need for labour augmentation was significantly    higher in nulliparas (47%) compared with multiparas (35%) (<i>P</i> = 0.001).    The interval from the initiation of oxytocin to delivery was statistically significantly    shorter in multiparas (mean 13.5 hours, SD 1.8 hours) compared with nulliparas    (mean 15.5 hours, SD 2.4 hours). Of the nulliparas 67% delivered within 16 hours    after oxytocin compared with 73% of multiparas (<i>P</i> = 0.001). </font></p>     <p><a name="tab02"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/emhj/v13n4/a14tab02.gif"></p>     <p>&nbsp;</p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">For women in      both groups (93%) who delivered within 24 hours of starting induction no more      than 2 × 3 mg PGE2 vaginal tablets were needed to achieve a clinically feasible      cervix for amniotomy. Women who took more than 24 hours from induction to      delivery needed 4 × 3 mg PGE2 tablets. There was no statistical significant      difference between the proportion of multiparas and nulliparas who took &gt;      24 hours from induction to delivery. Intrapartum complications showed no statistical      significant differences between the groups. Forceps delivery showed a statistically      significant difference in nulliparas (3%) compared with multiparas (1%) (<i>P</i>      = 0.001). Vaginal delivery was achieved in 86% of the whole study group. There      was no statistically significant difference in the caesarean section rate      between the groups, but descent arrest as a cause of caesarean delivery was      significantly more common among multiparas (3.5%) than nulliparas (2%) (<i>P</i>      = 0.007). </font></p>        <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#tab03">Table    3</a> presents the fetal outcomes of the study groups. There were no statistically    significant differences in the rate of perinatal deaths between the groups.    The main causes of death were: respiratory distress, birth asphyxia and congenital    anomaly. These causes could not be attributed to the use of intravaginal prostaglandin    E2. </font></p>     <p><a name="tab03"></a></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p align="center"><img src="/img/revistas/emhj/v13n4/a14tab03.gif"></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Five-minute Apgar    score &lt; 6 (<i>P</i> = 0.008), meconium presence at delivery (<i>P</i> = 0.001)    and admission to neonatal intensive care unit (<i>P</i> = 0.001) were all significantly    higher in nulliparas than in multiparas. Birth weight was significantly higher    among multiparas than nulliparas (<i>P</i> &lt; 0.0001). </font></p>     <p>&nbsp;</p>        <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">This study demonstrates      that the use of intravaginal PGE2 for cervical ripening as well as labour      induction in nulliparas and multiparas is safe and effective. This was demonstrated      by the high delivery rate before 24 hours (93%), and the low need of oxytocin      for labour augmentation (42%). Also there were no serious maternal or neonatal      side-effects attributable to the use of PGE2. </font></p>        <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The percentage    of multiparas who delivered within 16 hours after initiation of PGE2 (73%) was    significantly higher than nulliparas (67%). The overall vaginal delivery rate    of 86% in our study is comparable with that previously reported by Hassan &#91;<i>8</i>&#93;.    This finding would eliminate the option of elective caesarean delivery in women    who require delivery regardless of the Bishop score. This study revealed a short    induction-to-delivery interval of 93% within 24 hours (the great majority delivered    in less than 16 hours). This would indicate a short first stage of labour from    an increased uterine activity. This is in agreement with the findings of Egarter    et al. &#91;<i>9</i>&#93;. </font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The use of oxytocin      for labour augmentation was low in our study (used in 47% of primiparas and      35% of multiparas). This is in contrast to the report of Casey et al. &#91;<i>10</i>&#93;      who used vaginal prostaglandins even in the presence of a ripe cervix and      oxytocin was used in 75% of primiparas and 40% of multiparas in their study      group. The use of PGE2 for induction of labour appeared to be effective in      achieving cervical ripening, initiation of labour and optimal type of delivery;      this corresponds to that reported by D’Aniello et al. &#91;<i>11</i>&#93;. </font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Intrapartum complications      showed no statistically significant differences between the groups. Although      the most dangerous complication of induction of labour by PGE2 is rupture      of the uterus, this was seen most commonly where there is a previous lower      segment scar. There were no cases of rupture of the uterus in our patients.      This corresponds to other reports by MacKenzie et al. &#91;<i>12</i>&#93; and Al-Bar      et al. &#91;<i>13</i>&#93; which recorded no rupture of uterine scar following PGE2      induction, and disagrees with Ramsey et al. &#91;<i>14</i>&#93; and Raskin et al.      &#91;<i>15</i>&#93; who reported uterine rupture in women receiving PGE2 for labour      induction. Furthermore, the results of the current study revealed no statistically      significant differences in perinatal mortality between the groups. So there      were no apparently serious maternal or fetal complications. This corresponds      with the findings of Ben-Haroush et al. &#91;<i>16</i>&#93;.</font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">This study agrees      with other reports &#91;<i>13,17,18</i>&#93; regarding the use and safety of PGE2      vaginal tablets for labour induction, which showed a significant improvement      in cervical favourability within 24 hours resulting in an increase in successful      vaginal delivery rates in 24 hours and no increase in operative delivery rates.      </font></p>        ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">In the view of    these findings, cervical priming as well as labour induction using intravaginal    PGE2 is safe and effective and produces no harm attributable to the method.</font></p>     <p>&nbsp;</p>        <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>References</b></font></p>       <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Steiner AL,      Creasy RK. Methods of cervical ripening. <i>Clinical obstetrics and gynecology</i>,      1983, 26:37-46.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=001523&pid=S1020-3397200700040001500001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2.   Keirse MJ      Nc. Prostaglandins in preinduction cervical ripening: meta-analysis of worldwide      clinical, experience. <i>Journal of reproductive medicine</i>, 1993, 38:89-100.</font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3.   Heinberg      EM, Wood RA, Chambers RB. Elective induction of labour in multiparous women.      Does it increase the risk of cesarean section? <i>Journal of reproductive      medicine</i>, 2002, 47(5):399-403.</font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4.   Abou el-Leil      LA, Nasrat AA, Fayed HM. Prostaglandin E2 vaginal pessaries in the grandmultipara      with an unripe cervix, a comparison of different parity groups. <i>International      journal of gynaecology and obstetrics</i>, 1993, 40(2):119-20.</font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5.   Hales KA      et al. Double-blind comparison of intracervical and intravaginal prostaglandin      E2 for cervical ripening and induction of labor. <i>American journal of obstetrics      and gynecology</i>, 1994, 171:1087-91.</font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6.   Friedman      EA. The labour curve. <i>Clinics in perinatology</i>, 1981, 8:15.</font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7.   Seitchik      J, Castillo M. Oxytocin augmentation of dysfunctional labor. I. Clinical data.      <i>American journal of obstetrics and gynecology</i>, 1982, 144:899-905.</font></p>       ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8.   Hassan AA.      A Comparison of oral misoprostol tablets and vaginal prostaglandin E2 pessary      in induction of labour at term. <i>Journal of the College of Physicians and      Surgeons-Pakistan</i>, 2005, 15(5):284-7. </font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9.   Egarter      C et al. Erfahrungen bei 2149 Geburtseinleitungen mit 3 mg Prostaglandin-E2-Vaginaltabletten.      Eine retrospektive Analyse. &#91;Uterine activity in induction of labor by vaginal      administration of prostaglandin E2 tablet.&#93; <i>Zeitschrift für Geburtshilfe      und Perinatologie</i>, 1986, 190(3):129-32. </font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10.  Casey C,      Kehoe J, Mylotte MJ. Vaginal prostaglandins for the ripe cervix. <i>International      journal of gynaecology and obstetrics</i>, 1994, 44(1):21-6. </font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11.  D’Aniello      G et al. Cervical ripening and induction of labor by prostaglandin E2: a comparison      between intracervical gel and vaginal pessary. <i>Journal of maternal</i>-<i>fetal      and neonatal medicine</i>, 2003, 14(3):158-62.</font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12.  Mackenzie      IZ, Bradley S, Embrey MP. Vaginal prostaglandins and labour induction for      patients previously delivered by caesarean section. <i>British journal of      obstetrics and gynaecology</i>, 1984, 91:7-10.</font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13.  Al Bar H      et al. The experience with prostaglandin E2 vaginal tablets for induction      of labour in grand and great grand multiparae. A two year review in Saudi      Arabia. <i>Journal of obstetrics and gynecology</i>, 2000, 20:132-5.</font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14.  Ramsey PS,      Owen J. Midtrimester cervical ripening and labor induction. <i>Clinical obstetrics      and gynecology</i>, 2000, 43:495-512.</font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15.  Raskin KS      et al. Uterine rupture after use of a prostaglandin E2 vaginal insert during      vaginal birth after cesarean. A report of two cases. <i>Journal of reproductive      medicine</i>, 1999, 44:571-4. </font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16.  Ben-Haroush      A et al. Indicated labor induction with vaginal prostaglandin E2 increases      the risk of cesarean section even in multiparous women with no previous cesarean      section. Journal of perinatal medicine, 2004, 32(1):31-6.</font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17.  Sobande      AA, Al-Bar HM, Archibong EI. A comparison of spontaneous labor with induced      vaginal tablets prostaglandin E2 in grand multiparae. Saudi medical journal,      2001, 22(8):698-701.</font></p>       ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18.  Kelly AJ,      Kavanagh J, Thomas J. Vaginal prostaglandin (PGE2 and PGF2a) for induction      of labour at term. Cochrane database of systematic reviews, 2003, (4):CD003101.</font></p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> </font></p>       <p>&nbsp;</p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Received: 12/06/05;      accepted: 27/07/05 </font></p>       <p>&nbsp;</p>       <p>&nbsp;</p>       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Emergency      Preparedness and Humanitarian Action 1st Regional Training of Trainers on      Logistics Supply System</b> </font></p>        <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">A total of 25 pharmacists,    logisticians, supply officers, warehouse managers, emergency coordinators and    IT experts were trained from 23 to 26 April 2007 in Amman, Jordan in the “Logistics    Supply System”, WHO/UN software which enhances efficiency and transparency of    management of humanitarian supplies.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> Participants came    from the Islamic Republic of Iran, Iraq, Jordan, Lebanon, Sudan, Syria, and    the West Bank and Gaza and from different organizations: the United Nations    Relief and Works Agency for Palestine Refugees in the Near East, the World Food    Programme, the Ministry of Health and WHO.  </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The training is    part of a larger programme aiming to implement the system in several countries    in the Region and to ensure it is always used immediately after a natural disaster    or crisis occurs for the management of incoming donations.   </font></p>      ]]></body>
<body><![CDATA[ ]]></body>
<REFERENCES></REFERENCES<back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steiner]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Creasy]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Methods of cervical ripening]]></article-title>
<source><![CDATA[Clinical obstetrics and gynecology]]></source>
<year>1983</year>
<volume>26</volume>
<page-range>37-46</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
